pritelivir Report issue

Small molecule Experimental
AACT DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Pritelivir is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV). This is particularly important in immune compromised patients. Pritelivir is currently in Phase III clinical development by the German biopharmaceutical company AiCuris Anti-infective Cures AG.US FDA granted Fast Track Designation for pritelivir in 2017. US FDA granted Breakthrough Therapy Designation for pritelivir in 2020.   Wikipedia

Chemistry

  • SMILES: Cc1nc(N(C)C(=O)Cc2ccc(-c3ccccn3)cc2)sc1S(N)(=O)=O
  • InChIKey: IVZKZONQVYTCKC-UHFFFAOYSA-N
  • Mol. Mass: 402.5
  • ALogP: 2.37
  • ChEMBL Molecule:
    pritelivir  
More Chemistry

Pharmacology

Alternative names

aic316 | bay 57-1293 | n-(5-(aminiosulfonyl)-4-methyl-1,3-thiazol-2-yl)-n-methyl-2-(4-(2-pyridinyl)phenyl)acetamide | pritelivir

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Herpes Genitalis (Phase 2)

Herpes Labialis (Phase 2)

Herpes Simplex (Phase 2)

Herpesvirus 2, Human (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue